Leading Air Cargo Services Provider Purchases Implant Sciences' QS-B220 Explosives Trace Detectors
Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it has sold its QS-B220 desktop explosives trace detectors to a leading air cargo services provider, which provides TSA Certified Cargo Screening.
"The air cargo services providers are looking for new technologies to improve their operational capabilities and reduce operating costs," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones . "They view the QS-B220 as an integral component of this strategy, citing low cost of ownership, automatic calibration, ease of use and remote diagnostic capabilities. The value proposition offered by Implant Sciences is far superior to competing explosives trace technologies, coupled with highly customer focused aftermarket support are critical attributes to the decision makers."
Global and China 3D Laser Scanners Sales Market Report 2020
"Our technology, which truly is the new standard in trace detection, continues to be recognized by freight forwarders for its operational and cost advantages," commented Implant Sciences' Chief Executive Officer, Glenn D. Bolduc . "The needs of air cargo screening facilities were one of our prime considerations when we built the QS-B220. It's exciting to see our ideas validated by an industry leader."
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than competing products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Source : Implant Sciences Corporation - view original press release
Feb 21 - 23, 2017 - London, United Kingdom